🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our long-acting 'Global News' from other international teams last week includes: - Unitaid investing $22m to accelerate access to lenacapavir - Sirius Therapeutics with an update on a long-acting next-generation anticoagulant for thromboembolic disorders. liverpool.ac.uk/centre-of-exce…

10 December is United Nations Human Right's Day. Universal Declaration of Human Rights Article 25 is the right to adequate health, inc. medical care. We research long-acting medications. Medical care is only adequate if it's manageable. Reduced pill burden is needed. liverpool.ac.uk/centre-of-exce…

Next week, we'll be sending out the last #LONGEVITYproject newsletter of the year. These are a quick way of keeping up with key LONGEVITY LMIC HCV, malaria and TB news from the last three months, and upcoming events and opportunities. Subscribe below: liverpool.ac.uk/centre-of-exce…

Achieving universal health coverage (#UHC) demands adjustments at every level—from health systems to financing. Through partnerships, reduced costs and innovative solutions, Unitaid helps countries build stronger health systems, ensuring no one is left behind. #UHCDay

📢 End-of-Year Message from MPP Executive Director Charles Gore on the occasion of #UHCDay📢 ✨ As 2️⃣ 0️⃣ 2️⃣ 4️⃣ comes to a close, we reflect on a year of significant achievements and ongoing challenges in #GlobalHealth. From our transformative partnerships to advancements in

Last week's Global News updates from other international long-acting injectables research included: - A letter from UNAIDS Global for improved access to long-acting HIV medicine - Partnership news between Neuraxpharm and Pharmathen Read more in the link below: liverpool.ac.uk/centre-of-exce…

Do you use #PBPK modelling? Teoreler (with funding from Unitaid) is CELT's free #modellingsimulation software. It includes adult, children and drug-drug interaction models, with more in development. We're in beta and would really appreciate feedback. 👉liverpool.ac.uk/centre-of-exce…

After today, we're closed for the winter break. You're still welcome to send any queries you have our way, but please be aware we'll reply when we return in January. We hope you all enjoy your festivities, and we'll see you in 2025!

The start of a new year is a good time to remind people what our cross faculty team do. CELT work with partners to better understand how long-acting technologies can benefit patients with currently overly complicated drug regimens. Learn about us here: liverpool.ac.uk/centre-of-exce…

Have you seen the studentship currently available with CELT's Professor Neill Liptrott and UoM Materials' Dr Tom McDonald? This funded PhD is with the Biotechnology and Biological Sciences Research Northwest Doctoral Programme in Bioscience. Application deadline is 31 January. Find out more: liverpool.ac.uk/centre-of-exce…

Last week's Global News of other incredible long-acting therapeutics research includes exciting stories from: Xtalks Webinars Lyndra® Therapeutics & Thermo Fisher Novo Holdings and an incredible piece from GlaukosCorp showing drug efficacy after 36 months of a single dose. liverpool.ac.uk/centre-of-exce…

Upcoming Events: 23 Jan; Community of Practice: Long-acting therapeutics for maternal and paediatric health first meeting 9-12 March; We and University of Nebraska Medical Center present at Conference of Opportunistic Infections 21-22 May; Academic Medical Education's International Workshop on Long-acting Anti-infectives liverpool.ac.uk/centre-of-exce…

People affected by hepatitis C Virus (HCV) are enthusiastic about long-acting cure research, according to surveys in low- and middle-income countries by the Unitaid-funded LONGEVITY Project (of which TAG is a member). Read our statement on the findings: treatmentactiongroup.org/statement/comm…

TAG is coordinator of Long-Acting Technologies Community Advisory Board (LAT CAB), which helped disseminate surveys on community attitudes toward potential long-acting HCV cures under the Unitaid-funded LONGEVITY Project. This kind of community engagement offers vital insights👇

It's #WorldCancerDay. Did you know Hepatitis C Virus (HCV) is a common driver of liver cancer? Read TAG's statement on community attitudes toward a long-acting injectable HCV cure, based on surveys conducted under Unitaid-funded LONGEVITY project: treatmentactiongroup.org/statement/comm…

CELT's pharmacometrics team developed Teoreler, the only free to use, online simulation tool to describe the pharmacokinetics of drugs using different physiologically-based pharmacokinetic (PBPK) models. We'd value feedback from any of our Teoreler users. liverpool.ac.uk/centre-of-exce…

#February11 is International Day of Women and Girls in Science. For its 10th anniversary, we've written a blog in interview with @KimScarsi from LONGEVITY partner University of Nebraska Medical Center. Kim has an incredible research background and exciting recent accolade. Read more here liverpool.ac.uk/centre-of-exce…

🚨 Big things are happening in #LongActingTherapies—be part of the first-ever International Workshop on Long-Acting Anti-Infectives (LAAI) 2025! 📅21-22 May |📍New Orleans, LA, US P.S Abstract submissions are open! Submit by Friday, 28 Feb! 🔗amededu.co/4jRIxHd #LAAIWS